Sign In
Buy CBAY
$32.48
+0 (+0%)
At Close: Apr 11, 2024
CymaBay Therapeutics Inc (NASDAQ:CBAY) Shares Bought by Geode Capital Management LLC
04:14pm, Thursday, 16'th Jul 2020
Geode Capital Management LLC grew its stake in shares of CymaBay Therapeutics Inc (NASDAQ:CBAY) by 5.8% in the first quarter, according to the company in its most recent 13F filing with the Securities
Is CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Popular Amongst Institutions?
01:44pm, Sunday, 05'th Jul 2020
If you want to know who really controls CymaBay Therapeutics, Inc. (NASDAQ:CBAY), then you'll have to look at the...
Xconomy: FDA Says “No” to Intercept Pharma’s NASH Drug, Asks for More Data
06:08pm, Monday, 29'th Jun 2020
The FDA has rejected an Intercept Pharmaceuticals drug developed to treat the fatty liver disorder nonalcoholic steatohepatitis, more commonly referred to
Hedge Funds Keep Selling CymaBay Therapeutics Inc (CBAY)
11:20pm, Sunday, 28'th Jun 2020
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F
CymaBay: Live And Die By The FDA
02:34pm, Thursday, 25'th Jun 2020
An independent review panel unanimously concluded no evidence of liver injury from phase 2b Seladelpar clinical trial. CymaBay has a thin product pipeline with
CymaBay Therapeutics (NASDAQ:CBAY) Raised to Buy at Zacks Investment Research
03:18am, Thursday, 25'th Jun 2020
Zacks Investment Research upgraded shares of CymaBay Therapeutics (NASDAQ:CBAY) from a hold rating to a buy rating in a research note issued to investors on Monday morning, Zacks.com reports. Zacks In
CymaBay Seladelpar Data, And Other News: The Good, Bad And Ugly Of Biopharma
02:32pm, Tuesday, 23'rd Jun 2020
CymaBay posts positive data for seladelpar. Nabriva receives another CRL. Merck reports positive phase 3 data for its pneumonia vaccine.
Deutsche Bank AG Grows Position in CymaBay Therapeutics Inc (NASDAQ:CBAY)
08:16am, Monday, 22'nd Jun 2020
Deutsche Bank AG grew its holdings in CymaBay Therapeutics Inc (NASDAQ:CBAY) by 474.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. T
CymaBay Therapeutics (CBAY) Gets a Buy Rating from B.Riley FBR - Markets
07:20am, Monday, 22'nd Jun 2020
In a report released today, Mayank Mamtani from B.Riley FBR reiterated a Buy rating on CymaBay Therapeutics (CBAY – Research
CymaBay Therapeutics (NASDAQ:CBAY) Stock Rating Reaffirmed by B. Riley
04:02am, Monday, 22'nd Jun 2020
CymaBay Therapeutics (NASDAQ:CBAY)‘s stock had its “buy” rating restated by research analysts at B. Riley in a research report issued on Monday, TipRanks reports. They currently have a $6.00 pri
CymaBay Therapeutics Presents Data at Digestive Disease Week 2020 Online Education
12:00pm, Friday, 19'th Jun 2020
CymaBay Therapeutics, Inc. (CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced ne
Is the Options Market Predicting a Spike in CymaBay (CBAY) Stock?
12:45pm, Thursday, 18'th Jun 2020
Investors need to pay close attention to CymaBay (CBAY) stock based on the movements in the options market lately.
CymaBay Therapeutics Inc (NASDAQ:CBAY) Expected to Post Earnings of -$0.23 Per Share
07:20am, Monday, 15'th Jun 2020
Equities research analysts predict that CymaBay Therapeutics Inc (NASDAQ:CBAY) will announce ($0.23) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Ze
BlackRock Inc. Lowers Stock Holdings in CymaBay Therapeutics Inc (NASDAQ:CBAY)
04:10am, Wednesday, 10'th Jun 2020
BlackRock Inc. lowered its stake in shares of CymaBay Therapeutics Inc (NASDAQ:CBAY) by 1.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exch
